AcNK-Sup003
/ SupermAb (BeiJing) Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 17, 2026
Clinical Study on the Safety and Efficacy of CD20/CD19 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
(clinicaltrials.gov)
- P=N/A | N=28 | Not yet recruiting | Sponsor: Donghua Zhang
New trial • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
1 to 1
Of
1
Go to page
1